MapLight Therapeutics, Inc. MPLT
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -61.41%
- 1 year
- -59.93%
- Open
- 7.65
- Prev close
- 7.58
- Mkt cap
- 376.80M
- Vol
- 245.51K
- Avg vol
- 509.15K
- EPS
- -6.25
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.77
- High
- 7.67
- Forward P/E
- -10.51
- Beta
- 0.00
- Short ratio
- 5.58
- Inst. own
- 56.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 18, 2026
- 50-d avg
- 30.61
- 200-d avg
- 22.20
- 1y target
- 41.50
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
2 weeks ago defenseworld.net
Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in Stock
Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) CFO Jonathan Gillis sold 10,167 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold…
2 weeks ago defenseworld.net
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in Stock
Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider James Lillie sold 11,513 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold…
2 weeks ago defenseworld.net
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $96,024.32 in Stock
Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Anatol Kreitzer sold 12,248 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average…
2 weeks ago defenseworld.net
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $124,068.40 in Stock
Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Erin Pennock Foff sold 15,355 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at…
2 weeks ago zacks.com
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among…
2 weeks ago defenseworld.net
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Has Consensus Price Target of $29.50
Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) has received a consensus rating of "Moderate Buy" from the eighteen analysts that are currently covering the firm, Marketbeat reports. One…
2 weeks ago zacks.com
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street…
3 weeks ago globenewswire.com
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
Award honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight's circuit-based approach to…
1 month ago globenewswire.com
MapLight Therapeutics to Participate in Upcoming Investor Conference
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor…
2 months ago defenseworld.net
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT
BlackRock Inc. acquired a new position in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
-
2 months ago benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.
2 months ago globenewswire.com
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of…
-
2 months ago benzinga.com
MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders,…
2 months ago globenewswire.com
MapLight Therapeutics Announces $150 Million Private Placement Financing
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering…
-
2 months ago benzinga.com
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.
3 months ago prnewswire.com
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors…
3 months ago defenseworld.net
Maplight Therapeutics (NASDAQ:MPLT) Trading 18.2% Higher on Insider Buying Activity
Shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) rose 18.2% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $14.49 and last…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…
3 months ago defenseworld.net
ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT
ADAR1 Capital Management LLC acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) during the undefined quarter, according to the company in its most recent disclosure with the…
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.
-
3 months ago benzinga.com
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21
Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.
3 months ago seekingalpha.com
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
3 months ago marketbeat.com
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics NASDAQ: MPLT reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant…
3 months ago benzinga.com
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight Therapeutics Inc. (NASDAQ:MPLT) stock is trading lower on Monday after the company reported topline data from its Phase 2 ZEPHYR trial of ML-007C-MA, an oral M1/M4 muscarinic agonist…
3 months ago benzinga.com
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
3 months ago gurufocus.com
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
3 months ago businesswire.com
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MPLT--MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX)…
-
3 months ago benzinga.com
Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary Endpoint, With 210/3 Mg Twice-Daily Dose, While 330/6 mg Once-daily Dose Missed Primary Endpoint
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to…
-
3 months ago benzinga.com
UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.
-
3 months ago benzinga.com
BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46
BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $46.
-
3 months ago benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.
-
4 months ago benzinga.com
Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Target of $46
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Strong Buy rating and announces Price Target of $46.
-
4 months ago benzinga.com
Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $40.
-
4 months ago benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $37 to $42.
4 months ago benzinga.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.
-
4 months ago benzinga.com
MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder
The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses planned by age group and baseline irritability severity.As an exploratory signal-finding Phase 2 study,…
-
5 months ago benzinga.com
Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36
Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $28 to $36.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ:MPLT) with a Buy and maintains $45 price target.
-
5 months ago benzinga.com
UBS Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $48
UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $48.
-
5 months ago benzinga.com
Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43
Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $43.
-
5 months ago benzinga.com
MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over…
6 months ago benzinga.com
This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.
6 months ago benzinga.com
This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.
-
6 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $45
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $45.
-
6 months ago benzinga.com
MapLight Therapeutics Completes Enrollment In Its Phase 2 Zephyr Trial Evaluating Ml-007C-MA For The Treatment Of Schizophrenia
The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline…
6 months ago benzinga.com
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.